Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.

Corporate Profile

Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer.

Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounMore >>

EXEL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$23.59
Change (%) Stock is Down 1.31 (5.26%)
Volume4,642,689
Data as of 06/27/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
06/19/17Exelixis Announces Independent Radiology Committee Review Confirms Results from CABOSUN, the Phase 2 Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell CarcinomaPrinter Friendly Version
06/12/17Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid TumorsPrinter Friendly Version
06/08/17Exelixis to Present at the William Blair & Co. 37th Annual Growth Stock Conference on June 13Printer Friendly Version
05/03/17Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation2016 Annual Report (pdf)
Download Documentation2015 Annual Report (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.